WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Sunrise Genetics Inc.
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Cell and Gene Therapy
Puma Biotechnology | September 21, 2022
Puma Biotechnology, Inc. a biopharmaceutical company, announced an agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of aurora kinase A. Alisertib is an adenosine triphosphate–competitive and reversible inhibitor of aurora kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. Alisertib h...
Industry Outlook
prnewswire | May 08, 2023
Frost & Sullivan announced that it has awarded Genomenon with the 2023 Global Technology Innovation Leadership Award. Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables. Frost & Sullivan market analysts determined that Genomenon excels in many of the cri...
Repurpose.AI | July 01, 2020
Repurpose.AI, an AI drug discovery company, today announced the launch of an Open Innovation Partnership with LEO Pharma A/S, a global leader in medical dermatology, to discover and validate drugs to treat inflammatory and dermatology indications.The research collaboration will leverage Repurpose.AI's ActivPred AI Drug Discovery Platform, an unbiased drug, target and disease agnostic digital chemistry engine, to discover drug candidates for inflammatory skin diseases. Previously, the c...
Medical
Alligator Bioscience | December 07, 2020
Alligator Bioscience declares an affirmed IND (Investigational new Drug) for the CD40 targeting antibody mitazalimab. IND endorsement by the US Food and Drug Administration (FDA) is an essential to begin clinical preliminaries in the USA. As of late, new benchmark information was distributed indicating that mitazalimab can possibly be top tier in the CD40 field. The comparison demonstrated the potent immune-activating properties and anti-tumor effects of mitazalimab. "W...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE